TCGA data analysis revealed around 15 and 3% of lung adenocarcinoma patients had an amplification in the MCL-1 gene and BCL-xL gene, respectively (Fig. 1a), although no correlation between their amplification and the overall survival was established in these patients (Fig. S1A, B). Here, BCL2L1 is linked to lung adenocarcinoma.